Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More
05:59pm, Monday, 01'st Aug 2022 Zacks Investment Research
Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
02:29pm, Monday, 01'st Aug 2022 Zacks Investment Research
Higher demand for its key drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
02:00pm, Monday, 01'st Aug 2022 Zacks Investment Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Xgeva, Repatha, and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
3 Biotech Stock Picks From This Wedbush Analyst
09:27pm, Wednesday, 27'th Jul 2022 Benzinga
While the S&P 500 index peaked in January and has had a rough year, the biotech sector peaked last August. For the time being, both have found a short-term and possible long-term bottom in June.
Dav
Denali Therapeutics Inc. (DNLI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
02:02pm, Wednesday, 27'th Jul 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Stock Jumps 15.3%: Will It Continue to Soar?
01:06pm, Friday, 22'nd Jul 2022 Zacks Investment Research
Repligen (RGEN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Benzinga's Top Ratings Upgrades, Downgrades For July 8, 2022
02:02pm, Friday, 08'th Jul 2022 Benzinga
Upgrades
According to Wedbush, the prior rating for Diebold Nixdorf Inc (NYSE:DBD) was changed from Neutral to Outperform. Diebold Nixdorf earned $1.61 in the first quarter, compared to $0.29 in the
Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion
08:42am, Thursday, 30'th Jun 2022
Shares of Blueprint Medicines Corp. BPMC, -2.34% gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma RPRX, -1.10% , whi
Wells Fargo Cuts Targets and Coverage on Carnival and More
09:25am, Wednesday, 29'th Jun 2022
After last week's rally, markets have been under pressure this week, giving more credence to a bear market rally.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
03:16pm, Friday, 17'th Jun 2022 Zacks Investment Research
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry
12:20pm, Friday, 17'th Jun 2022
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022
02:10pm, Friday, 10'th Jun 2022 Benzinga
Upgrades
According to Wedbush, the prior rating for SciPlay Corp (NASDAQ:SCPL) was changed from Neutral to Outperform. In the first quarter, SciPlay showed an EPS of $0.18, compared to $0.21 from the
4 Analysts Have This to Say About Blueprint Medicines
01:16pm, Friday, 10'th Jun 2022 Benzinga
Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
0
2
0
1
L
Bluebird (BLUE) Down 6.2% Since Last Earnings Report: Can It Rebound?
03:30pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?
03:31pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
